Secondary BRCA1 and BRCA2 alterations and acquired chemoresistance

Cancer Biology and Therapy

Volumn 7, Issue 7, 2008, Pages 1004-1005

  Wang, Weixin ^a   Figg, William D ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

BRCA1; BRCA2; Cisplatin; Inhibitor; Mutation; PARP; Resistance

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CISPLATIN; DOCETAXEL; DOUBLE STRANDED DNA; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PLATINUM DERIVATIVE;

ALLELE; BREAST CANCER; CANCER MORTALITY; CANCER RESISTANCE; DNA REPAIR; DNA SEQUENCE; DNA STRAND BREAKAGE; FRAMESHIFT MUTATION; GENE FUNCTION; GENE MUTATION; HUMAN; NEOPLASM; NOTE; OPEN READING FRAME; OVARY CANCER; PROTEIN EXPRESSION; TUMOR GROWTH; TUMOR SUPPRESSOR GENE; WILD TYPE;

EID: 47949128413     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.7.7.6409     Document Type: Note

References (16)

1. Narod SA and Foulkes WD. BRCA1 and BRCA2: 1994 and beyond. Nat Rev Cancer 2004; 4:665-76.
2. Venkitaraman AR. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 2002; 108:171-82.
3. Farmer H, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434:917-21.
4. Bryant HE, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005; 434:913-7.
5. Ratnam K and Low JA. Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology. Clin Cancer Res 2007; 13:1383-8.
6. Edwards SL, et al. Resistance to therapy caused by intragenic deletion in BRCA2. Nature 2008; 451:1111-5.
7. Sakai W, et al. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature 2008; 451:1116-20.
8. Swisher EM, et al. Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance. Cancer Res 2008; 68:2581-6.
9. Neuhausen S, et al. Recurrent BRCA2 6174delT mutations in Ashkenazi Jewish women affected by breast cancer. Nat Genet 1996; 13:126-8.
10. Goggins M, et al. Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res 1996; 56:5360-4.
11. Struewing JP, et al. The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals. Nat Genet 1995; 11:198-200.
12. Ferry KV, Hamilton TC and Johnson SW. Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells: role of ERCC1-XPF. Biochem Pharmacol 2000; 60:1305-13.
13. Reed E. Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy. Cancer Treat Rev 1998; 24:331-44.
14. Aebi S, et al. Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res 1996; 56:3087-90.
15. Brown R, et al. hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents. Oncogene 1997; 15:45-52.
16. Drummond JT, et al. Cisplatin and adriamycin resistance are associated with MutLalpha and mismatch repair deficiency in an ovarian tumor cell line. J Biol Chem 1996; 271:19645-8.